Durata Therapeutics Inc., of Morristown, N.J., completed target enrollment of 556 patients in DISCOVER 1 (Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response), one of two ongoing, global, Phase III trials of lead candidate dalbavancin in acute bacterial skin and skin structure infections (abSSSI).
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST